The $350M PIPE and reverse merger effectively recapitalize TCRT with a new pipeline and substantial cash runway. Monitor the stockholder meeting timeline for preferred stock conversion approval, which will determine when the new investors' and Velaris holders' shares convert to common stock and become tradable.
Price Chart
Executive Summary
Alaunos Therapeutics (TCRT) has entered into a definitive merger agreement to acquire Velaris Therapeutics in a reverse merger structured as a reorganization, valuing Velaris at $200 million and Alaunos at $15 million. Concurrently, Alaunos raised $350 million in a PIPE financing from investors including Fairmount Healthcare Fund II. The combined entity will operate under the Velaris name and focus on Velaris' pipeline. The merger closed substantially simultaneously with the signing of the agreement.
Key Financial Metrics
Key Facts
- Alaunos Therapeutics (TCRT) agreed to acquire Velaris Therapeutics in a reverse merger with an agreed valuation of $200 million for Velaris and $15 million for Alaunos.
- Concurrent PIPE financing of $350 million from investors including Fairmount Healthcare Fund II closed simultaneously with the merger.
- Velaris stockholders will receive shares of Alaunos Series B and Series C Convertible Preferred Stock as merger consideration.
- The combined company will be renamed Velaris Therapeutics, Inc. and focus on Velaris' pipeline programs.
- The merger closed on October 13, 2026, the same date the agreement was signed.
- Alaunos' legacy business (including ALN1003 and TCR-T programs) will be wound down.
- A stockholder meeting will be held to approve conversion of the preferred stock, a name change, a reverse stock split, a redomestication to the Cayman Islands, and a new equity incentive plan.
Financial Impact
Velaris valued at $200M; Alaunos valued at $15M pre-cash; $350M PIPE financing provides substantial capital for combined entity's pipeline development.
Risk Factors
- Stockholder approval required for preferred stock conversion and other proposals; failure could delay conversion and liquidity events.
- Execution risk on Velaris' pipeline programs; the combined entity is pre-revenue.
- Dilution from the PIPE and merger consideration; existing TCRT shareholders will own a small fraction of the combined company.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-419829 |
| Document: tcrt-ex10_1.htm | 0001193125-26-419829 |
| Document: tcrt-ex10_2.htm | 0001193125-26-419829 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.13 | awaiting T+20 | — | $2.06 (−3.29%) |
Oct 21, 2026 6d ago | 8-K | $3.04 | awaiting T+20 | — | $2.06 (−32.24%) |
Oct 15, 2026 12d ago | SC 13D/A | $2.63 | awaiting T+20 | — | $2.06 (−21.67%) |
Oct 15, 2026 12d ago | SC 13D | $2.63 | awaiting T+20 | — | $2.06 (−21.67%) |
Oct 13, 2026 14d ago | Press Release | $3.03 | awaiting T+20 | — | $2.06 (−32.01%) |
Oct 13, 2026 14d ago | 8-K | $3.03 | awaiting T+20 | — | $2.06 (−32.01%) |
Oct 9, 2026 18d ago | 8-K | $1.05 | awaiting T+20 | — | $2.06 (−96.19%) |
Sep 18, 2026 5w ago | Press Release | $1.20 $2.63 | ▼ −119.17% | ▼ −118.96% | $2.06 (−71.67%) |
Sep 16, 2026 5w ago | 8-K | $1.60 $2.18 | ▲ +36.25% | ▲ +34.79% | $2.06 (+28.75%) |
Jun 29, 2026 17w ago | 8-K | $2.37 $1.94 | ▼ −18.14% | ▼ −17.86% | $2.06 (−13.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers